Supportive Neurology: Valuing Increased Function and Improved QoL in Treatment of Non-Core Symptoms of Neurological Disease
August 4, 2016
- Ginger Johnson, PhD, CEO, Defined Health
- Todd Sherer, PhD, Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF)
Patients with various neurological conditions have commonly occurring symptoms (e.g., fatigue, cognitive dysfunction, sleep disturbance, psychosis, agitation) that are not considered core diagnostic criteria, but nonetheless are highly troubling and negatively impact daily function and QoL. While tremendous and very much necessary efforts are focused on disease modifying therapies, patients remain in need of relief from non-core symptoms impacting daily life. Recent advances in what we refer to as “supportive neurology”, such as the FDA approval of Acadia’s Nuplazid (pimavanserin) for the treatment of psychosis in Parkinson’s disease (PD) patients, has heightened interest in this space. With a growing pipeline of development-stage agents targeting indications such as hallucinations and behavioral disturbance in Lewy Body Dementia (Axovant Sciences), cognitive impairment in PD (Biotie/Acorda) and respiratory function in amyotrophic lateral sclerosis (Cytokinetics), this webinar will review development activity in supportive neurology, highlighting promising programs and outlining commercial and strategic considerations.
In this webinar, Ginger Johnson, PhD is joined by Todd Sherer, PhD, Chief Executive Officer of The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to discuss advances in PD supportive care as well as how these programs may lead to treatments for additional indications.